MetaVia Inc. announced the completion of the final patient visit for its extended 24-week Phase 1 Part 3A study of DA-1726. The company is preparing for a 48-week Phase 2 trial in MetALD and ALD patients, targeted for the second half of 2027, following positive interim data showing significant reductions in liver fat and body weight.
MetaVia reports the last patient completed the extended 24-week Phase 1 visit for DA-1726 at the 48 mg dose and cites previously reported Part 3B interim results: a 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss at Day 109, with all five steatosis patients falling below 5% MRI-PDFF. These are hard, quantified data points supporting the planned 48-week Phase 2 in MetALD/ALD in the second half of 2027. However, the key interim figures were already released, so the new information is mainly trial progress and timelines, which limits the incremental price effect
- ▲ Completion of last patient visit in the extended 24-week Phase 1 Part 3A study (announced November 17, 2026)
- ▲ Full data from Parts 3A and 3B expected in the first quarter of 2027
- ▼ Results are preliminary safety and tolerability observations, not full efficacy data
- ▼ Full Parts 3A and 3B results are only due in Q1 2027 and could differ from interim figures